AI Article Synopsis
- Research on giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) has gained importance recently, as physicians encounter challenges in diagnosing and treating these conditions, necessitating the search for helpful biomarkers.
- The review highlights various clinical situations where biomarkers can aid in diagnosis, predict relapses or complications, monitor disease activity, and guide treatment decisions for GCA and PMR.
- It discusses the broad range of biomarkers studied, including common markers like C-reactive protein and more specific inflammatory indicators, while stressing the need for consistency and careful evaluation in research on GCA and PMR biomarkers.
Article Abstract
Research into giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) has become more important in the last few decades. Physicians are facing several challenges in managing the diagnosis, treatment, and relapses of GCA and PMR patients. The search for biomarkers could provide elements to guide a physician's decision. In this review, we aim to summarize the scientific publications about biomarkers in GCA and PMR in the past decade. The first point raised by this review is the number of clinical situations in which biomarkers could be useful: differential diagnosis of either GCA or PMR, diagnosis of underlying vasculitis in PMR, prediction of relapse or complications, disease activity monitoring, choice, and modification of treatments. The second point raised by this review is the large number of biomarkers studied, from common markers like C-reactive protein, erythrocyte sedimentation rate, or elements of blood count to inflammatory cytokines, growth factors, or immune cell subpopulations. Finally, this review underlines the heterogeneity between the studies and proposes points to consider in studies evaluating biomarkers in general and particularly in the case of GCA and PMR.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313393 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1202160 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Different giant cell arteritis phenotypes may present distinct types of ischaemic complications.
Clin Exp Rheumatol
December 2024
Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain.
Objectives: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischaemic complications (IC) in giant cell arteritis (GCA).
Methods: Retrospective observational analysis of GCA clinically confirmed patients referred to US fast-track clinics at two centres. All patients underwent baseline US of cranial and extracranial arteries (carotid, subclavian and axillary).
Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.
Reumatologia
November 2024
Department of Primary Care, Health District of Soverato, Azienda Sanitaria Provinciale Catanzaro, Italy.
Introduction: The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases of PMR following the coronavirus disease 2019 (COVID-19) have revived the role of infection as an aetiological or triggering factor. It is estimated that patients with PMR have manifestations of giant cell arteritis (GCA) in < 20% of cases.
View Article and Find Full Text PDFBaricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases.
Reumatismo
October 2024
Division of Rheumatology, "La Colletta" Hospital, Azienda Sociosanitaria Ligure 3, Arenzano.
Article Synopsis
- This case series evaluates the effectiveness and safety of baricitinib (BARI) in treating six patients suffering from polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), particularly when traditional treatments like tocilizumab were unavailable.
- Patients showed significant improvement in symptoms, with a notable reduction in their disease activity scores and the ability of some to discontinue glucocorticoids while on BARI.
- Overall, the findings align with previous studies indicating that Janus kinase inhibitors may serve as a helpful alternative for managing PMR and GCA by reducing reliance on glucocorticoids, although one patient did experience pneumonia after treatment.
Purpose Of Review: There have been advances in the diagnosis and treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Recent Findings: Themes in PMR and GCA include classification criteria, ultrasound imaging of temporal and axillary arteries replacing biopsies for diagnosis of GCA, faster diagnosis and treatment with rapid access clinics for suspected GCA, and expanding treatment options with the goal of rapid suppression of inflammation and sparing steroids.
Summary: Treatment is aimed at suppressing inflammation quickly in both GCA and PMR.
Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns.
Front Med (Lausanne)
September 2024
Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Although its role has been debated, temporal artery biopsy (TAB) remains the gold standard for the diagnosis of cranial giant cell arteritis (GCA). The specificity of TAB is excellent and the sensitivity, albeit lower, is comparable with other diagnostic modalities used for the diagnosis of GCA. This outpatient procedure has a low rate of complications and is well integrated in the majority of healthcare systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!